
Together, the 3 products reduce cramps, bloating, heaviness, fatigue, and mood swings, giving complete, 360° period comfort, fitting right into your routine lifestyle.
3 STEPS COMFORT ROUTINE
1.
2.
3.
In just 15 minutes, this 3-step routine helps a woman feel normal again, so period feels like just another day.
Absolutely yes!
Together, they cover everything your body goes through so you feel normal again.
✦ Painfree pads
give external, all-day relief.
✦ Cramp relief Gel
gives instant, targeted relief
✦ Debloat Superfood
gives internal, long-lasting relief
Summary of the studies conducted
| Study Name | Study Type / Model | Key Findings / Results | Conclusion / Outcome |
|---|---|---|---|
| 1. Skin Irritation Study | In-vivo (6 male Wistar rats) | Draize scores: 0.0-0.5; no erythema, edema, or irritation observed; normal histopathology | Non-irritant and well-tolerated upon repeated dermal exposure |
| 2. Carrageenan-Induced Paw Edema Study | In-vivo anti-inflammatory model (18 Wistar rats) | Significant reduction in paw edema vs control; inhibition comparable to NSAID reference drug | Confirms strong anti-inflammatory and prostaglandin-suppressing activity |
| 3. Acute Oral Toxicity Study | In-vivo (15 albino rats) | No mortality or systemic toxicity; normal histopathology and stable body weight | Safe at high oral doses; LD₅₀ exceeds tested limits |
| 4. Experimental Dysmenorrhea Rat Model | In-vivo (Oxytocin-induced uterine contraction model) | Significant reduction in writhing behavior and PGF₂α levels; superior to Mefatal-Spas | Demonstrated superior spasmolytic and prostaglandin-modulating action |
| 5. Human Pilot Study - Cramp Relief Gel & Debloat Superfood (n = 90) | Randomized controlled pilot (90 women, 3 cycles) | Onset of action within 10-30 sec; 90% achieved >80% pain reduction; no side effects | Significantly faster, safer, and more effective than NSAIDs and home remedies |
| 6. In-vitro Dissolution Study | Simulated vaginal fluid (SVF) | Rapid release within 1 min; sustained release up to 8 hrs; diffusion-controlled mechanism (R² ≈ 0.98) | Optimized biphasic release ensuring instant + long-lasting relief |
| 7. Vaginal Irritation Study | In-vivo (New Zealand white rabbits) | No erythema, edema, or abnormal discharge; normal histopathology | Classified as non-irritant to vaginal mucosa; highly biocompatible |
| 8. Cytotoxicity Study (L929 Fibroblasts) | In-vitro cell viability assay | >90% cell viability across all concentrations; normal morphology | Non-cytotoxic; safe for dermal and mucosal contact |
| 9. Skin Sensitization Study | In-vivo (Wistar rats, ISO 10993-10) | No erythema, edema, or lymphoid activation; histopathology normal | Non-sensitizing and safe for prolonged dermal use |
| 10. Therapeutic Efficacy in Dysmenorrhea Model | In-vivo (Rat model) | Reduced writhing, normalized uterine histology; PGF₂α ↓ to 35-40 ng/mL, PGE₂ undetectable, TNF-α < assay detection | Potent anti-dysmenorrheic efficacy; equal or greater than NSAIDs |
| 11. Anti-Inflammatory Evaluation (Carrageenan Model) | In-vivo (Rat model, ISO 10993-11) | 65.36% inhibition of inflammation at 6 h (NSAID: 118.79%); p < 0.01 | Strong topical anti-inflammatory action validating NSAID-like efficacy |
| 12. Human Observational Study- Sanitary Pad (n=30) | Prospective open-label, 3 menstrual cycles | Pain reduced from VAS 7.4 → 2.1 (p < 0.001); >70% reduction in bloating; 87% strong user preference; no AEs | Clinically effective, safe, and well-tolerated; improved comfort and function |
Summary of the studies conducted
| Study Name | Study Type / Model | Key Findings / Results | Conclusion / Outcome |
|---|---|---|---|
| 1. Skin Irritation Study | In-vivo (6 male Wistar rats) | Draize scores: 0.0-0.5; no erythema, edema, or irritation observed; normal histopathology | Non-irritant and well-tolerated upon repeated dermal exposure |
| 2. Carrageenan-Induced Paw Edema Study | In-vivo anti-inflammatory model (18 Wistar rats) | Significant reduction in paw edema vs control; inhibition comparable to NSAID reference drug | Confirms strong anti-inflammatory and prostaglandin-suppressing activity |
| 3. Acute Oral Toxicity Study | In-vivo (15 albino rats) | No mortality or systemic toxicity; normal histopathology and stable body weight | Safe at high oral doses; LD₅₀ exceeds tested limits |
| 4. Experimental Dysmenorrhea Rat Model | In-vivo (Oxytocin-induced uterine contraction model) | Significant reduction in writhing behavior and PGF₂α levels; superior to Mefatal-Spas | Demonstrated superior spasmolytic and prostaglandin-modulating action |
| 5. Human Pilot Study - Cramp Relief Gel & Debloat Superfood (n = 90) | Randomized controlled pilot (90 women, 3 cycles) | Onset of action within 10-30 sec; 90% achieved >80% pain reduction; no side effects | Significantly faster, safer, and more effective than NSAIDs and home remedies |
| 6. In-vitro Dissolution Study | Simulated vaginal fluid (SVF) | Rapid release within 1 min; sustained release up to 8 hrs; diffusion-controlled mechanism (R² ≈ 0.98) | Optimized biphasic release ensuring instant + long-lasting relief |
| 7. Vaginal Irritation Study | In-vivo (New Zealand white rabbits) | No erythema, edema, or abnormal discharge; normal histopathology | Classified as non-irritant to vaginal mucosa; highly biocompatible |
| 8. Cytotoxicity Study (L929 Fibroblasts) | In-vitro cell viability assay | >90% cell viability across all concentrations; normal morphology | Non-cytotoxic; safe for dermal and mucosal contact |
| 9. Skin Sensitization Study | In-vivo (Wistar rats, ISO 10993-10) | No erythema, edema, or lymphoid activation; histopathology normal | Non-sensitizing and safe for prolonged dermal use |
| 10. Therapeutic Efficacy in Dysmenorrhea Model | In-vivo (Rat model) | Reduced writhing, normalized uterine histology; PGF₂α ↓ to 35-40 ng/mL, PGE₂ undetectable, TNF-α < assay detection | Potent anti-dysmenorrheic efficacy; equal or greater than NSAIDs |
| 11. Anti-Inflammatory Evaluation (Carrageenan Model) | In-vivo (Rat model, ISO 10993-11) | 65.36% inhibition of inflammation at 6 h (NSAID: 118.79%); p < 0.01 | Strong topical anti-inflammatory action validating NSAID-like efficacy |
| 12. Human Observational Study- Sanitary Pad (n=30) | Prospective open-label, 3 menstrual cycles | Pain reduced from VAS 7.4 → 2.1 (p < 0.001); >70% reduction in bloating; 87% strong user preference; no AEs | Clinically effective, safe, and well-tolerated; improved comfort and function |
WHY WOMEN PREFER...